Back to News
Market Impact: 0.3
1ST Biotherapeutics, SK Biopharma Sign Up To $314.8M Deal For Parkinson's Drug 1ST-104
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureProduct Launches
1ST Biotherapeutic and SK Biopharmaceuticals announced an exclusive global licensing agreement and strategic equity-investment partnership to advance 1ST-104, an investigational oral small-molecule treatment for Parkinson's disease. The partnership provides validation and financing support for the clinical candidate, though financial terms and development milestones were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Altman Says AI Will Transform the Economics of Energy
- Citizens reiterates Ondas Holdings stock rating on IonStrike updates